Evidence map›Paper›PMID 38976686›Full record

ArticleChemMedChem2024

Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 Inhibitors.

Sravan K Jonnalagadda, Ling Duan, Louise F Dow, Geetha P Boligala, Elizabeth Kosmacek, Kristyn McCoy, Rebecca Oberley-Deegan, Yashpal Singh Chhonker, Darryl J Murry, C Patrick Reynolds and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Sravan K JonnalagaddaDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
Ling DuanCenter of Excellence in Environmental Toxicology, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States.
Louise F DowDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
Geetha P BoligalaSchool of Medicine Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States.
Elizabeth KosmacekDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
Kristyn McCoySchool of Medicine Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States.
Rebecca Oberley-DeeganDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
Yashpal Singh ChhonkerDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, 68106, USA.
Darryl J MurryFred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.
C Patrick ReynoldsSchool of Medicine Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States.
Barry J MaurerSchool of Medicine Cancer Center, Texas Tech University Health Sciences Center, Lubbock, Texas, 79430, United States.
Trevor M PenningCenter of Excellence in Environmental Toxicology, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States.
Paul C TrippierDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, 68106, United States.ORCID https://orcid.org/0000-0002-4947-5782

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI A. Clementina Mesaros · 2006 to 2026
$35.3M
AKR1C Inhibitors as Chemotherapeutic PotentiatorsR01CA226436 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI TRIPPIER, PAUL · 2019 to 2023
$2.0M
NCI NIH HHS R01 CA226436NIEHS NIH HHS P30 ES01308NIEHS NIH HHS P30 ES013508
6 · The paper itself

Abstract

A series of 7-substituted coumarin derivatives have been characterized as pan-aldo-keto reductase family 1C (AKR1C) inhibitors. The AKR1C family of enzymes are overexpressed in numerous cancers where they are involved in drug resistance development. 7-hydroxy coumarin ethyl esters and their corresponding amides have high potency for AKR1C3 and AKR1C2 inhibition. Coumarin amide 3 a possessed IC

Indexed as

Aldo-Keto Reductase Family 1 Member C3CoumarinsEnzyme Inhibitors3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)3-Hydroxysteroid DehydrogenasesAnimalsAntineoplastic AgentsCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansHydroxyprostaglandin DehydrogenasesHydroxysteroid DehydrogenasesMiceMicrosomes, Liver3-alpha-Hydroxysteroid Dehydrogenase (B-Specific)3-Hydroxysteroid DehydrogenasesAKR1C2 protein, humanAKR1C3 protein, humanAldo-Keto Reductase Family 1 Member C3Antineoplastic AgentsCoumarinsEnzyme InhibitorsHydroxyprostaglandin DehydrogenasesHydroxysteroid DehydrogenasesAKR1C2 InhibitorAKR1C3 InhibitorDrug ResistanceLeukemiaProstate Cancer

Identifiers

PMID38976686
PMCPMC11537819

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.